Literature DB >> 10829070

A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase.

A B Satterthwaite1, F Willis, P Kanchanastit, D Fruman, L C Cantley, C D Helgason, R K Humphries, C A Lowell, M Simon, M Leitges, A Tarakhovsky, T F Tedder, R Lesche, H Wu, O N Witte.   

Abstract

Modifier screens have been powerful genetic tools to define signaling pathways in lower organisms. The identification of modifier loci in mice has begun to allow a similar dissection of mammalian signaling pathways. Transgenic mice (Btk(lo)) expressing 25% of endogenous levels of Bruton's tyrosine kinase (Btk) have B cell functional responses between those of wild-type and Btk(-/-) mice. We asked whether reduced dosage or complete deficiency of genes previously implicated as Btk regulators would modify the Btk(lo) phenotype. We used two independent assays of Btk-dependent B cell function. Proliferative response to B cell antigen receptor cross-linking in vitro was chosen as an example of a relatively simple, well-defined signaling system. In vivo response to type II T-independent antigens (TI-II) measures complex interactions among multiple cell types over time and may identify additional Btk pathways. All modifiers identified differentially affected these two assays, indicating that Btk mediates these processes via distinct mechanisms. Loss of Lyn, PTEN (phosphatase and tensin homolog), or SH2-containing inositol phosphatase suppressed the Btk(lo) phenotype in vitro but not in vivo, whereas CD19 and the p85alpha form of phosphoinositide 3-kinase behaved as Btk(lo) enhancers in vivo but not in vitro. Effects of Lyn, PTEN, or p85alpha haploinsufficiency were observed. Haploinsufficiency or complete deficiency of protein kinase C beta, Fyn, CD22, Galphaq, or Galpha11 had no detectable effect on the function of Btk(lo) B cells. A transgenic system creating a reduction in dosage of Btk can therefore be used to identify modifier loci that affect B cell responses and quantitatively rank their contribution to Btk-mediated processes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10829070      PMCID: PMC18703          DOI: 10.1073/pnas.110146697

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  78 in total

1.  Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule.

Authors:  P Engel; L J Zhou; D C Ord; S Sato; B Koller; T F Tedder
Journal:  Immunity       Date:  1995-07       Impact factor: 31.745

2.  CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice.

Authors:  S Sato; A S Miller; M Inaoki; C B Bock; P J Jansen; M L Tang; T F Tedder
Journal:  Immunity       Date:  1996-12       Impact factor: 31.745

Review 3.  Random mutagenesis screen for dominant behavioral mutations in mice.

Authors:  P M Nolan; D Kapfhamer; M Bućan
Journal:  Methods       Date:  1997-12       Impact factor: 3.608

4.  X-linked immune deficiency (xid) of CBA/N mice.

Authors:  L S Wicker; I Scher
Journal:  Curr Top Microbiol Immunol       Date:  1986       Impact factor: 4.291

5.  Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases.

Authors:  D J Rawlings; A M Scharenberg; H Park; M I Wahl; S Lin; R M Kato; A C Fluckiger; O N Witte; J P Kinet
Journal:  Science       Date:  1996-02-09       Impact factor: 47.728

6.  Btk dosage determines sensitivity to B cell antigen receptor cross-linking.

Authors:  A B Satterthwaite; H Cheroutre; W N Khan; P Sideras; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 7.  T cell-independent antigens type 2.

Authors:  J J Mond; A Lees; C M Snapper
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

8.  The G protein G alpha12 stimulates Bruton's tyrosine kinase and a rasGAP through a conserved PH/BM domain.

Authors:  Y Jiang; W Ma; Y Wan; T Kozasa; S Hattori; X Y Huang
Journal:  Nature       Date:  1998-10-22       Impact factor: 49.962

9.  RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development.

Authors:  J Chen; R Lansford; V Stewart; F Young; F W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

10.  Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways.

Authors:  A B Satterthwaite; C A Lowell; W N Khan; P Sideras; F W Alt; O N Witte
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

View more
  10 in total

1.  Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes.

Authors:  David A Fruman; Gregory Z Ferl; Sam S An; Amber C Donahue; Anne B Satterthwaite; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

Review 2.  Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.

Authors:  Justin M Drake; John K Lee; Owen N Witte
Journal:  Mol Cell Biol       Date:  2014-02-24       Impact factor: 4.272

3.  A balance between B cell receptor and inhibitory receptor signaling controls plasma cell differentiation by maintaining optimal Ets1 levels.

Authors:  Anne B Satterthwaite; Wei Luo; Jessica Mayeux; Toni Gutierrez; Lisa Russell; Andrew Getahun; Jennifer Müller; Thomas Tedder; Jane Parnes; Robert Rickert; Lars Nitschke; John Cambier; Lee Ann Garrett-Sinha
Journal:  J Immunol       Date:  2014-06-13       Impact factor: 5.422

4.  Spatiotemporal patterning during T cell activation is highly diverse.

Authors:  Kentner L Singleton; Kole T Roybal; Yi Sun; Guo Fu; Nicholas R J Gascoigne; Nicolai S C van Oers; Christoph Wülfing
Journal:  Sci Signal       Date:  2009-04-07       Impact factor: 8.192

5.  The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.

Authors:  Betty Y Chang; Min Mei Huang; Michelle Francesco; Jun Chen; Jeremy Sokolove; Padmaja Magadala; William H Robinson; Joseph J Buggy
Journal:  Arthritis Res Ther       Date:  2011-07-13       Impact factor: 5.156

6.  Silencing of B cell receptor signals in human naive B cells.

Authors:  Niklas Feldhahn; Ines Schwering; Sanggyu Lee; Maria Wartenberg; Florian Klein; Hui Wang; Guolin Zhou; San Ming Wang; Janet D Rowley; Jürgen Hescheler; Martin Krönke; Klaus Rajewsky; Ralf Küppers; Markus Müschen
Journal:  J Exp Med       Date:  2002-11-18       Impact factor: 14.307

Review 7.  Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus.

Authors:  Anne B Satterthwaite
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

8.  Editorial: Targeting Bruton Tyrosine Kinase.

Authors:  Cornelia Brunner; Annika C Betzler; Jennifer R Brown; Amy H Andreotti; Emanuela Grassilli
Journal:  Front Cell Dev Biol       Date:  2022-04-26

Review 9.  BTK, the new kid on the (oncology) block?

Authors:  Emanuela Grassilli; Maria Grazia Cerrito; Marialuisa Lavitrano
Journal:  Front Oncol       Date:  2022-08-04       Impact factor: 5.738

10.  Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus.

Authors:  Jack Hutcheson; Kamala Vanarsa; Anna Bashmakov; Simer Grewal; Deena Sajitharan; Betty Y Chang; Joseph J Buggy; Xin J Zhou; Yong Du; Anne B Satterthwaite; Chandra Mohan
Journal:  Arthritis Res Ther       Date:  2012-11-08       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.